Trade Desk (NASDAQ:TTD – Get Free Report) was downgraded by stock analysts at Evercore ISI from an “outperform” rating to an “inline” rating in a research note issued to investors on Thursday, ...

Teradata (NYSE:TDC – Free Report) had its target price cut by Evercore ISI from $37.00 to $32.00 in a research report report ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.